226 related articles for article (PubMed ID: 34450497)
1. Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
Soltan OM; Shoman ME; Abdel-Aziz SA; Narumi A; Konno H; Abdel-Aziz M
Eur J Med Chem; 2021 Dec; 225():113768. PubMed ID: 34450497
[TBL] [Abstract][Full Text] [Related]
2. Promising Targets in Anti-cancer Drug Development: Recent Updates.
Kumar B; Singh S; Skvortsova I; Kumar V
Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
[TBL] [Abstract][Full Text] [Related]
3. Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment.
Ceramella J; Iacopetta D; Barbarossa A; Caruso A; Grande F; Bonomo MG; Mariconda A; Longo P; Carmela S; Sinicropi MS
Mini Rev Med Chem; 2020; 20(6):444-465. PubMed ID: 31951166
[TBL] [Abstract][Full Text] [Related]
4. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.
Liu XJ; Zhao HC; Hou SJ; Zhang HJ; Cheng L; Yuan S; Zhang LR; Song J; Zhang SY; Chen SW
Bioorg Chem; 2023 Apr; 133():106425. PubMed ID: 36801788
[TBL] [Abstract][Full Text] [Related]
5. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-).
Hu L; Fan M; Shi S; Song X; Wang F; He H; Qi B
Eur J Med Chem; 2022 Jan; 227():113963. PubMed ID: 34749202
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
Marak BN; Dowarah J; Khiangte L; Singh VP
Eur J Med Chem; 2020 Oct; 203():112571. PubMed ID: 32707525
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
[TBL] [Abstract][Full Text] [Related]
8. Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900320. PubMed ID: 32285482
[TBL] [Abstract][Full Text] [Related]
9. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
10. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
Carlino L; Rastelli G
J Med Chem; 2016 Oct; 59(20):9305-9320. PubMed ID: 27559828
[TBL] [Abstract][Full Text] [Related]
11. Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy.
Ali AM; Tawfik SS; Mostafa AS; Massoud MAM
Chem Biol Drug Des; 2022 Nov; 100(5):656-673. PubMed ID: 35962624
[TBL] [Abstract][Full Text] [Related]
12. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.
Hesham HM; Lasheen DS; Abouzid KAM
Med Res Rev; 2018 Sep; 38(6):2058-2109. PubMed ID: 29733427
[TBL] [Abstract][Full Text] [Related]
13. Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.
Ayati A; Moghimi S; Toolabi M; Foroumadi A
Eur J Med Chem; 2021 Oct; 221():113523. PubMed ID: 33992931
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present).
Abdel-Mohsen HT; Anwar MM; Ahmed NS; Abd El-Karim SS; Abdelwahed SH
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398626
[TBL] [Abstract][Full Text] [Related]
15. Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review.
Kwiecień H; Goszczyńska A; Rokosz P
Curr Pharm Des; 2016; 22(7):879-94. PubMed ID: 26648467
[TBL] [Abstract][Full Text] [Related]
16. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
Hameed R; Khan A; Khan S; Perveen S
Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
[TBL] [Abstract][Full Text] [Related]
17. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
Thakur A; Singla R; Jaitak V
Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
[TBL] [Abstract][Full Text] [Related]
18. An update on chemical classes targeting ERK1/2 for the management of cancer.
Pathania S; Rawal RK
Future Med Chem; 2020 Apr; 12(7):593-611. PubMed ID: 32191540
[TBL] [Abstract][Full Text] [Related]
19. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.
Ikram N; Mirza MU; Vanmeert M; Froeyen M; Salo-Ahen OMH; Tahir M; Qazi A; Ahmad S
Biomolecules; 2019 Mar; 9(4):. PubMed ID: 30925835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
